2022 World Conference on Lung Cancer (ePosters)-EP08.02-056. Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors

EP08.02-056. Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors

Back to course

Pdf Summary

Researchers have reported a case of a patient with non-small cell lung cancer who had a complete response to MET inhibitors. MET inhibitors are a type of precision medicine that targets specific genetic mutations in lung malignancies. In this case, the patient had both a MET exon 14 skipping mutation and a gene amplification of MET. The patient was treated with the MET inhibitor tepotinib and experienced rapid and durable control of the disease.<br /><br />The patient was a 64-year-old man who had experienced weight loss and back pain for three months. Tests revealed a lung adenocarcinoma with metastasis to the lymph nodes, bones, and liver. Genetic testing showed the presence of the MET exon 14 skipping mutation and gene amplification of MET. The patient initially received pembrolizumab, carboplatin, and pemetrexed as first-line treatment, but his symptoms worsened and disease progression was observed. He then started treatment with crizotinib, an off-label drug, which led to significant clinical improvement and partial tumor regression.<br /><br />In February 2021, the patient started on tepotinib through a compassionate use program. After two months, he achieved a complete radiologic response, and one year later, he remains on treatment without evidence of disease.<br /><br />This case highlights the potential for a complete and durable response to MET inhibitors when both a MET mutation and gene amplification are present. The high allele fraction of the MET exon 14 skipping mutation suggests that these genetic events occurred in the same allele and are present in all cancer cells. This underscores the importance of comprehensive molecular characterization in understanding the response to targeted therapies in non-small cell lung cancer.

Asset Subtitle

Flávia Amaral Duarte

Meta Tag

Speaker Flávia Amaral Duarte

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

non-small cell lung cancer

MET inhibitors

precision medicine

MET exon 14 skipping mutation

gene amplification of MET

tepotinib

lung adenocarcinoma

pembrolizumab

crizotinib

radiologic response